Is 18F FDG PET-CT cost effective in lung cancer?

Area of Science:

• Medical imaging technologies
• Oncology
• Radiology

Background:

• Medical advances increasingly rely on technology, with positron emission tomography-computed tomography (PET-CT) offering combined functional and anatomical imaging.
• Accurate staging of non-small-cell lung cancer (NSCLC) is crucial for curative treatment (surgery or radiotherapy), but conventional CT imaging has limitations in determining disease extent.
• Futile thoracotomies in NSCLC patients due to inaccurate staging lead to significant morbidity and healthcare expenses.

Purpose of the Study:

• To evaluate the effectiveness of (18)F fluorodeoxyglucose PET-CT in assessing disease load in non-small-cell lung cancer patients.
• To determine if PET-CT can improve clinical decision-making and reduce unnecessary surgical interventions.
• To assess the potential cost-effectiveness of implementing PET-CT in the management of NSCLC.

Main Methods:

• Utilized (18)F fluorodeoxyglucose PET-CT scans for imaging patients with non-small-cell lung cancer.
• Compared the diagnostic accuracy of PET-CT with conventional CT in determining disease extent and nodal involvement.
• Analyzed the impact of PET-CT findings on treatment decisions, specifically regarding surgical eligibility.

Main Results:

• Evidence suggests (18)F fluorodeoxyglucose PET-CT is a superior discriminator of disease load in NSCLC compared to CT alone.
• PET-CT imaging can accurately identify patients with limited disease suitable for curative treatment.
• Implementation of PET-CT in the appropriate clinical setting is associated with a reduction in futile thoracotomies and associated costs.

Conclusions:

• (18)F fluorodeoxyglucose PET-CT is a valuable tool for accurate staging of non-small-cell lung cancer.
• Utilizing PET-CT can significantly decrease the number of unnecessary and morbid surgical procedures.
• PET-CT has the potential to optimize resource allocation and reduce overall healthcare expenditure in NSCLC management.